In breast cancer survivors, lidocaine may relieve pain during intercourse
the ONA take:
According to a new study published online in the Journal of Clinical Oncology, researchers at Oregon Health and Science University have found that breast cancer survivors who experience pain or discomfort during sexual intercourse may benefit from applying liquid lidocaine to the vulvar area.
Results of the study showed that the application of liquid lidocaine achieved reduced sexual distress and pain during intercourse, as well as improved sexual function. Participants applied the aqueous lidocaine 3 minutes prior to vaginal penetration.
Participants were estrogen-deficient breast cancer survivors. Low estrogen is known to be associated with pain during sexual intercourse.
"The physical and psychological consequences for the more than 2.8 million breast cancer survivors in the U.S. are very real and often misunderstood, or not treated," said Martha F. Goetsch, M.D., M.P.H., adjunct assistant professor in the OHSU Department of Obstetrics and Gynecology, the study's lead author. "This noninvasive treatment will offer distinct help in alleviating the physical—and quite frankly the emotional—pain associated with sexual intercourse, making sexual function more enjoyable and fulfilling for them and their partner."
Breast cancer survivors who experience pain or discomfort during sexual intercourse may benefit from applying liquid lidocaine to the vulvar area.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|